Lilly faces biosimilar rivals to osteoporosis drug Forsteo i...

CHMP says no to Amgen’s osteoporosis drug Evenity

At long last, Amgen/UCB score FDA okay for Evenity

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns.

FDA advisers back Amgen/UCB's osteoporosis drug Evenity

Amgen’s bone-building drug Evenity looks on course for US approval in certain women with osteoporosis after a panel of advisers strongly backed it, but cardiac safety worries mean that it w

Japan approves Amgen's osteoporosis drug

Amgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers to the US regulator later this month.

Amgen and UCB re-file Evenity for US approval

Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that the additional data they have provided will help overcome the FDA’s pre